
Challenges of Cold Chain Product in The Global Supply Chain
Speakers
Damian Larrington Pharmaceutical Quality Professionals - Pharmaceutical Quality Professionals
Dr Simon Baker PQG
Speakers
Speaker
Speaker
Polymorph expert Ruwanthi Gurusinghe will talk Custom Pharma Services' approach to the screening of Pharamceutical Polymorphs.
More than 50% of commercially available drug candidates have more than one polymorphic form. Each morph may show differences in their physicochemical properties such as dissolution rate, bioavailability, physical and chemical stability. Various mechanical and environmental factors may cause unintentional transformations between different polymorphs. The presentation will cover:
An overview to the polymorphism.
Speaker
Back in 1998, the World Health Organisation (WHO) stated that there were more than 500 deaths worldwide in the previous 60 years caused by use of falsified excipients. Since then, even very recently, further examples have occurred within the supply chain with dramatic impact caused for example by criminal activity, contamination, mislabelling, or upgrading of industrial grade material manufactured under non-GMP conditions.
As a result, the supply chain of pharmaceutical starting materials, in this case excipients, has been identified by regulators and industry as an important part of medicinal product safety. In a globalised world, excipients are supplied across continents and handled by an increasing
number of different parties. The increasing complexity of the global supply chain brings with it an increased risk in excipient security.
This workshop will seek to show how all parties within the supply chain can be supported (e.g. pharmaceutical excipient manufacturers, distributors, traders, brokers, re-packers,
carriers, warehouse providers) and detail some tools which are available to ensure supply chain security and support global drug safety.
Format:
Hear from experts on what’s required to adequately secure the storage and distribution of excipients and join in the discussion as to how this can be demonstrated to the satisfaction of all parties involved. The session has these key objectives:
Having registered to attend Making Pharmaceuticals, or Distributing Pharmaceuticals, register your place on the workshop HERE
Speakers
Speaker
Speaker
Speaker
From raw material qualification, in-process monitoring to finished product analysis, Raman Spectroscopy offers time and cost savings for process and bioprocess quality control. Discover how you can optimize your bioprocess workflows with handheld and portable Raman analysers.
Speaker
Speaker
Speaker
Speaker
Speaker
Overview:
In 2022 a new word just entered the Collins English Dictionary. ‘Permacrisis – an extended period of instability and insecurity’. This will present unique challenges and opportunities to everyone in the Pharma Industry. Important questions must be answered:
Format:
This will be a PowerPoint free zone! To achieve deep learning and personal development the session will be highly interactive and involve group work and problem solving. The session has three key objectives:
Session Duration: 2.5 hours
This workshop must be pre-booked, and by individuals who have already registered to attend Making Pharmaceuticals or Distributing Pharmaceuticals. Applicants will be notified 2 weeks before the event whether they have a place on the workshop.
Please book your place HERE
Speaker
Speakers
Richard Tarrant was responsible for the final QP certification of the first batch of COVID-19 vaccine to enter clinical trials in Europe, the Oxford-AstraZeneca vaccine, and provided various support in efforts relating to material supply for clinical trials and emergency use authorisation. In this talk, Richard will discuss the role of a clinical trial QP and how the small team at the Clinical BioManufacturing Facility (CBF) in Oxford were able manufacture, QP certify and release clinical trial material so rapidly and the various challenges encountered up until the point of emergency use authorisation.
Speaker
Speaker
Presentation looks at exploring the benefits and requirements of holding a pharmaceutical wholesale licence, giving an overview of basic requirements to get set up and maintaining a wholesale licence alongside other business activities.
Speakers
Speaker
Speaker
CellShip® is a novel and potentially disruptive cell transportation and storage medium developed through a highly successful three-year Knowledge Transfer Partnership (KTP) between Life Science Group (LSG) and Coventry University. The Knowledge Transfer Partnership (KTP) is a national programme, partly funded by Innovate UK, designed to help businesses improve their competitiveness and productivity through partnerships with universities.
The KTP between LSG and Coventry University was awarded the highest grade of “Outstanding” by the KTP Grading Panel for its achievement in meeting KTP’s Objectives.
CellShip® is a liquid buffer that allows for the transport of cells at ambient temperatures without the requirement for cryopreservation. This could allow for the shipment of hybridomas, primary cells and other cells between researchers at ambient temperatures while maintaining the integrity and effectiveness of the cells. This product could also be extremely disruptive for cell and gene therapy manufacturing, allowing cells to be delivered to the patient at ambient temperatures without apoptosis that occurs following freeze/thaw cycles. This would also mean that harmful cryoprotectants would not be required.
An important benefit to note is that the protocol requires minimal cell manipulation.
It also reduces the risk of contamination and improves efficiency within the laboratory. To date, Cellship® is validated for up to 120 h of transport/storage at ambient temperatures. It is a cost-effective, safe, novel, and viable alternative to the storage and transportation of cells using standard cryopreservation methods, a useful tool, not only for research purposes but potentially suitable for biomanufacturing and transportation of Advanced Therapy Medicinal Products (ATMPs).
Speaker
Speaker
Regardless of technology, there are always considerations for any manufacturing process to get the best from it. This unique presentation, delivered by an internationally recognised 3D print expert with 20 years of experience in 3D printing describes how transformative the power of 3D printing can be when applied correctly and how these same principles are already being adopted by the pharmaceutical industry to drive profitability, productivity, and business risk reduction.
Speaker
Speaker
Speaker
Speaker
Assuring successful aseptic manufacturing of sterile requires an understanding of the difficulties and limitations of test methods employed.
Various current methods are discussed as to their strengths and weaknesses.
Speaker
Covid 19 pandemic changed the dynamics of pharmaceutical companies and how they operate. It facilitated the research-based alliances and changed the perception toward partnership in the industry. The need for collaboration between competitors obligated companies to maintain the balance between collaboration and competition. The distribution of new molecules in different countries and region requires new levels of engagement, mainly in emerging economies. Pharmaceutical companies are seeking to conduct partnership with local partners in different regions to minimise the cost of distribution. The partnership between companies can be assessed to create many opportunities for competitive learning between partners.
Speaker
Speakers
An overview of the regulatory requirements for training. GMP and GDP expectations with regards to training. How these requirements can be achieved in practice. Evaluation of an individual’s training needs – what they know already and what they need to be trained in. How to evaluate training and its effectiveness. Different learning styles and catering for these in training sessions.
Speaker
Speaker
Speaker